Clinical Trials Logo

Lupus Erythematosus, Systemic clinical trials

View clinical trials related to Lupus Erythematosus, Systemic.

Filter by:

NCT ID: NCT01101802 Completed - Atherosclerosis Clinical Trials

Mycophenolate Mofetil in Systemic Lupus Erythematosus (MISSILE)

MISSILE
Start date: March 2006
Phase: Phase 4
Study type: Interventional

Systemic lupus erythematosus (SLE) is an independent risk factor for atherosclerosis. Endothelial dysfunction is the earliest marker of atherosclerosis and is measured by flow mediated dilation (FMD) of the brachial artery. The purpose of the study was to measure FMD in mild, stable SLE patients and look for change in FMD with the immunosuppressant drug mycophenolate mofetil (MMF).

NCT ID: NCT01093911 Completed - Autoimmune Diseases Clinical Trials

Safety Study of CDP7657 in Healthy Volunteers and Patients With Systemic Lupus Erythematosus (SLE)

Start date: March 2010
Phase: Phase 1
Study type: Interventional

To evaluate safety, tolerability, pharmacokinetics and immunogenicity of CDP7657

NCT ID: NCT01085097 Completed - Lupus Nephritis Clinical Trials

A Study of Laquinimod in Participants With Systemic Lupus Erythematosus (SLE) Active Lupus Nephritis

Start date: September 1, 2010
Phase: Phase 2
Study type: Interventional

The study aims to evaluate the safety and clinical effect of daily oral treatment with laquinimod capsules in active lupus nephritis participants. This study will assess Laquinimod doses of 0.5 milligrams (mg)/day and 1 mg/day in combination with standard of care treatment (mycophenolate mofetil [MMF] and corticosteroids). Laquinimod is a novel immunomodulating drug which is currently in advanced stages of development by Teva Pharmaceuticals Ltd. for Multiple Sclerosis.

NCT ID: NCT01085084 Completed - Lupus Arthritis Clinical Trials

A Study of Laquinimod in Participants With Systemic Lupus Erythematosus (SLE) Active Lupus Arthritis

Start date: October 4, 2010
Phase: Phase 2
Study type: Interventional

The study aims to evaluate the safety and clinical effect of daily oral treatment with laquinimod capsules (0.5 milligrams [mg] and 1 mg) in participants with active lupus arthritis. Laquinimod is a novel immunomodulating drug which is currently in advanced stages of development by Teva Pharmaceuticals Ltd. for Multiple Sclerosis.

NCT ID: NCT01076101 Completed - Clinical trials for Systemic Lupus Erythematosus

Autoimmunity in Sisters of Lupus Patients

SisSLE
Start date: February 2009
Phase: N/A
Study type: Observational [Patient Registry]

This study enrolled over 400 unaffected sisters of young women diagnosed with SLE. These unaffected sisters are being followed with an annual health questionnaire (CSQ) and blood sample.

NCT ID: NCT01072734 Completed - Clinical trials for Systemic Lupus Erythematosus (SLE)

Auto-immunity in Lupus Patients After Influenza Vaccine

GRIPLUP
Start date: September 2009
Phase: Phase 2
Study type: Interventional

Annual influenza vaccination is recommended in patients with systemic lupus erythematosus (SLE). However some concerns remain about vaccination and the risk of lupus flare

NCT ID: NCT01060410 Completed - Clinical trials for Lupus Erythematosus, Systemic

Exploration of Genotype Based Personalized Prescription of Cyclophosphamide in Systemic Lupus Erythematosus Treatment

Start date: May 2010
Phase: N/A
Study type: Observational

The purpose of this study is to investigate the relationship between the side effects of cyclophosphamide in the treatment of systemic lupus erythematosus (SLE) in Han Chinese and the genetic polymorphisms of drug metabolizing enzymes and pharmacokinetics of cyclophosphamide.

NCT ID: NCT01058343 Completed - Clinical trials for Systemic Lupus Erythematosus

Safety of IFNa Kinoid in Systemic Lupus Erythematosus

Start date: March 2010
Phase: Phase 1/Phase 2
Study type: Interventional

Interferon alpha (IFNa) is involved in the pathogenesis of systemic lupus erythematosus (SLE)and IFNa levels are associated with the severity of the disease. Blocking IFNa could be an attractive therapeutic strategy. Active immunization with IFNa kinoid (IFN-K) induces a polyclonal antibody response. This study will evaluate the safety of IFN-K in patients with mild to moderate SLE. It will also measure the induction of anti-IFNa antibodies and evaluate the clinical impact on SLE disease.

NCT ID: NCT01031836 Completed - Clinical trials for Systemic Lupus Erythematosus

A Study to Evaluate Safety and Tolerability of IV or SC Dose of MEDI-545 in Patients With Systemic Lupus Erythematosus.

Start date: November 25, 2009
Phase: Phase 2
Study type: Interventional

The purpose of the study is to evaluate the safety and tolerability of MEDI-545 in Japanese adult SLE patients. This will be done by collecting the data from 3 cohorts of IV doses and 1 cohort of SC doses.

NCT ID: NCT01031797 Completed - SLE Clinical Trials

QT Dispersion in Patients With Systemic Lupus Erythematosus (SLE)

Start date: January 2008
Phase: N/A
Study type: Observational

QT dispersion can be a useful, simple noninvasive method for the early detection of cardiac involvement in SLE patients with active disease. The investigators therefore recommend cardiovascular evaluation for every SLE patient with an SLEDAI higher than 10.